Guidelines on NSTE-ACS (version 2015) - Task Force

Transcription

1 Guidelines on NSTE-ACS (version 2015) - Task Force Andreotti Felicita - Pfizer (see also BMS) : apixaban ( ) - BMS-Pfizer : apixaban, cardiovascular metabolism ( ) - Bayer Schering Pharma : aspirin, rivaroxaban ( ) - Eli Lilly : prasugrel ( ) - Amgen : dyslipidemia ( ) - Daiichi Sankyo : edoxaban ( ) - Daiichi Sankyo-Eli Lilly : edoxaban, prasugrel (2013) - Pfizer : apixaban (2014) - BMS : apixaban, cardiovascular metabolism (2014) - Bayer Schering Pharma : aspirin (2015) Bax Jeroen Nothing to be declared ( ) - Boehringer-Ingelheim : non-vitamin k antagonist oral anticoagulants (2015) - Daiichi Sankyo : non-vitamin k antagonist oral anticoagulants (2015) - Pfizer : non-vitamin k antagonist oral anticoagulants (2015) - BMS-Pfizer : non-vitamin k antagonist oral anticoagulants (2015) - Servier : Farma ( ) - Edwards Lifesciences : Heart Valves ( ) - GE Healthcare : Imaging ( ) - Lantheus Inc : Imaging ( ) - Boston Scientific : Pacing ( ) - Medtronic : Pacing ( ) 1/50

2 Guidelines on NSTE-ACS (version 2015) - Task Force Bax Jeroen - St Jude Medical : Pacing ( ) - Biotronik : Pacing ( ) Borger Michael A - Edwards Lifesciences : heart valve therapy ( ) - St. Jude Medical : heart valve therapy ( ) - Medtronic : heart valve therapy ( ) - Sorin Group : heart valve therapy ( ) Brotons Carlos - Edwards Lifesciences : heart valve therapy (2015) - Pfizer : Apixaban ( ) - Bayer : Aspirin ( ) - Astra Zeneca : Brilinta (2014) - Lundbeck : Selincro ( ) Chew Derek - Astra Zeneca : Anti-platelet therapy ( ) - Abbott Vascular : Mitral Clip ( ) - Astra Zeneca : Antiplatelet therapy ( ) - Medscape : Physician Education ( ) - Astra Zeneca : Anti-platelet therapy ( ) - Astra Zeneca : Antiplatelet ( ) Collet Jean-Philippe - Astra Zeneca : antiplatelet (2012) - Eli Lilly : antiplatelet (2012) - Medco Health Solutions : antiplatelet (2012) 2/50

3 Guidelines on NSTE-ACS (version 2015) - Task Force Collet Jean-Philippe - Accumetrics : antiplatelet agents (2012) - Bristol Myers Squibb : antiplatelet and anticoagulant (2012) - Medtronic : valves (2012) - Bristol Myers Squibb : apixaban ( ) - Eli Lilly : prasugrel ( ) - Bayer : rivaroxaban ( ) - Daiichi Sankyo : EDOXABAN ( ) - Astra Zeneca : TICAGRELOR ( ) - Eli Lilly : prasugrel (2013) - Bristol Myers Squibb : apixaban ( ) - Medtronic : COREVALVE ( ) Gencer Baris Nothing to be declared ( ) Hasenfuss Gerd - CVRx : Baroreceptor stimulator (2012) - Servier : Ivabradine, RYCALS ( ) - Impulse Dynamics : Optimizer ( ) - Novartis : serelaxine ( ) - Circulite : Assist device ( ) - DC Devices : REDUC ELAP device trial ( ) - Astrazeneca : Therapeutic ( ) - Bayer : Xarelta ( ) - CVRx : Baroreceptor Stimulation (2015) 3/50

4 Guidelines on NSTE-ACS (version 2015) - Task Force Hasenfuss Gerd - Circulite : Assist Device (2012) - Astra Zeneca : Brilique (2012) - Bayer : rivaroxaban (2012) - Servier : RYCALS (2012) Kjeldsen Keld Per Nothing to be declared ( ) Lancellotti Patrizio - Boston Scientific : Heart Failure (2012) - Servier : Heart Failure (2013) - Abbott : MitraClip (2013) - Menarini : nebivolol (2014) - St Jude Medical : Heart Failure (2015) - Astra Zeneca : Brilique (2012) - Servier : Coversyl (2012) - Abbott Vascular : MitraClip (2012) - Astrazeneca : Dyslipidemia (2013) - Boston Scientific : CRT (2014) - Servier : procoralan (2014) - Daiichi Sankyo : Teaching course on imaging (2015) Landmesser Ulf - Actelion : Pulmonary Hypertension (2013) - Sanofi Aventis : Cardiovascular Research (2012) - Roche Pharma : Cardiovascular Research ( ) 4/50

5 Guidelines on NSTE-ACS (version 2015) - Task Force Landmesser Ulf - Amgen : Advisory Board, Speakers fee ( ) - Sanofi Aventis : Advisory Board, Speakers fee ( ) - MSD : Advisory Board, Speakers fee ( ) - Roche Pharma : Research grant, Advisory Board ( ) - Pfizer : Research grant, Speakers fee ( ) - St. Jude : Advisory Board (2015) Mehilli Julinda - Roche Diagnostics : Antithrombotic drugs ( ) - Lilly/Daiichi Sankyo : Antithrombotic drugs ( ) - Biotronik : PCI ( ) - Terumo Inc : PCI ( ) - Abbott Vascular : PCI ( ) - Daiichi Sankyo : Drugs ( ) - Edwards Lifesciences : Prosthesis ( ) - Terumo Inc : Stents ( ) - Abbott Vascular : Stents ( ) Mueller Christian Eugen - Alere : Diagnostics (2012) - Novartis : Acute Heart FAilure ( ) - BRAHMS GmbH : Diagnostics ( ) - Roche Diagnostics : Diagnostics ( ) - Cardiorentis : Acute Heart Failure ( ) - Abbott Laboratories : Diagnostics ( ) 5/50

6 Guidelines on NSTE-ACS (version 2015) - Task Force Mueller Christian Eugen - BG medicine : Diagnostics ( ) - BioMérieux S.A : Diagnostics ( ) - Siemens : Diagnostics ( ) - Bristol Myers Squibb : Anticoagulation ( ) - Astra Zeneca : Antiplatelet therapy ( ) - Daiichi Sankyo : Antiplatelet therapy ( ) - Lilly : Antiplatelet therapy ( ) - Singulex : Diagnostics ( ) - Sanofi Aventis : Lipids ( ) - Medicines Company : Acuet Heart FAilure (2012) - Swiss Heart Foundation : Diagnostics (2012) - Beckman Coulter : Diagnostics (2012) - Nanosphere : Diagnostics (2012) - BRAHMS GmbH : Diagnostics ( ) - Abbott Laboratories : Diagnostics ( ) - Roche Diagnostics : Diagnostics ( ) - Siemens : Diagnostics ( ) - Singulex : Diagnostics ( ) - BioMérieux S.A : Diagnostics ( ) - Sphingotec : Diagnostics ( ) - Astra Zeneca : Perioperative care ( ) 6/50

7 Guidelines on NSTE-ACS (version 2015) - Task Force Mukherjee Debabrata C - Receipt of royalties for intellectual property. - Wolters Kluwer Publishers : Textbook of Cardiology ( ) - Informa Healthcare Publishers : Textbook of Cardiology ( ) - Informa Healthcare Publishers : Cardiac catheterization Textbook ( ) Patrono Carlo - Astra Zeneca : Ticagrelor, PPI (2012) - Bayer : Aspirin ( ) - Eli Lilly : Prasugrel ( ) - Merck Sharp & Dohme : Vorapaxar ( ) Roffi Marco - Bayer AG : Aspirin ( ) - Daiichi Sankyo : antiplatelet therapy ( ) - Lilly : antiplatelet therapy ( ) - Astra Zeneca : antipletelet therapy ( ) - Johnson & Johnson : coronary catheters (2014) - Biosensors : devices ( ) - Boston Scientific : devices ( ) - Medtronic : devices ( ) - Biotronik : devices ( ) - Abbott Vascular : devices ( ) Storey Robert - Eisai : Atopaxar (2012) - Bristol Myers Squibb : Clopidogrel (2012) - Sanofi Aventis : Clopidogrel/PCSK9 inhibitor/otamixaban (2012) 7/50

8 Guidelines on NSTE-ACS (version 2015) - Task Force Storey Robert - Novartis : Elinogrel (2012) - Daiichi Sankyo : Prasugrel (2012) - Eli Lilly : Prasugrel (2012) - Iroko Cardio : Tirofiban (2012) - Merck Sharp & Dohme : Vorapaxar (2012) - Regeneron : PCSK9 inhibitor ( ) - Roche Pharma : PPAR antagonist ( ) - Accumetrics : VerifyNow device ( ) - Medscape : Antiplatelet therapy ( ) - Astra Zeneca : Ticagrelor ( ) - Sanofi Aventis : PCSK9 inhibitor/otamixaban (2013) - The Medicines Company : Cangrelor ( ) - ThermoFisher Scientific : Diagnostics ( ) - Aspen : Fondaparinux ( ) - PlaqueTec : Thrombosis research ( ) - Correvio : Tirofiban ( ) - Daiichi Sankyo : Prasugrel (2012) - Eli Lilly : Prasugrel (2012) - Accumetrics : VerifyNow device ( ) - Astra Zeneca : Ticagrelor ( ) - Eli Lilly : Prasugrel (2012) 8/50

9 Guidelines on NSTE-ACS (version 2015) - Task Force Storey Robert - Merck Sharp & Dohme : Vorapaxar (2012) - Accumetrics : VerifyNow ( ) - Astra Zeneca : Ticagrelor ( ) Valgimigli Marco - Accumetrics : Platlet Function Assay ( ) - Medtronic : stent ( ) - Abbott Laboratories : stent ( ) - Abbott Vascular : stent ( ) - Cordis : stent ( ) - CID : stent ( ) - Chiesi Pharma : tirofiban ( ) - Terumo Inc : Interventional cardiology ( ) - Astra Zeneca : ticagrelor ( ) - Iroko Cardio : Tirofiban ( ) - Alvimedical : stent (2014) - Astra Zeneca : Anti-thrombotic in ACS (2014) - Astra Zeneca : P2Y12 inhibitor (2015) Windecker Stephan - Biosensors : Stent (2012) - Boston Scientific : Stent (2012) - Cordis : Stent (2012) - Edwards Lifesciences : TAVI (2012) - Astra Zeneca : Antiplatelet drug ( ) 9/50

10 Guidelines on NSTE-ACS (version 2015) - Task Force Windecker Stephan - Eli Lilly : Antiplatelet drug ( ) - Abbott : Stent ( ) - Medtronic : Stent ( ) - Biotronik : Stent ( ) - Astra Zeneca : Antiplatelet therapy ( ) - Eli Lilly : Antiplatelet therapy ( ) - Bayer Healthcare : Antithrombotic drug ( ) - Abbott : Stent and Heartvalvetherapy ( ) - Biosensors : Stents ( ) - Boston Scientific : Stents ( ) - Medtronic : TAVI, Stent (2015) - Edwards Lifesciences : Transcatheter heart valves (2015) - Biosensors : Stent (2012) - Medtronic : Stent (2012) - Cordis : Stent (2012) - St Jude Medical : OCT ( ) - Biotronik : Stent ( ) - Abbott : Stent ( ) - Medtronic : Stent and Heartvalves (2014) - Medicines Company : Antithrombotic therapy ( ) - Johnson & Johnson : Catheters ( ) 10/50

11 Guidelines on NSTE-ACS (version 2015) - Task Force Windecker Stephan - Edwards Lifesciences : Heartvalves ( ) - Boston Scientific : Stent and Heartvalves ( ) 11/50

12 Abir-Khalil Saadia - Novartis : cardiology ( ) - Pfizer : cardiology ( ) - Sanofi Aventis : cardiology ( ) - Servier : cardiology (2013) - Sanofi Aventis : cardiology (2013) Achenbach Stephan - Bayer : Anticoagulation (2013) - Behring : Anticoagulation (2013) - Astra Zeneca : Antiplatelet Therapy (2013) - Abbott : Coronary Intervention (2013) - Siemens Healthcare : CT (2013) - Servier : Imaging (2013) - Guerbet : Imaging (2013) - Abbott : Coronary Intervention ( ) - Siemens Healthcare : Imaging ( ) Agewall Stefan - Böhringer Ingelheim : Anticoagulatn treatment (2013) - Roche Diagnostics : Cardiac markers (2013) - Orion : Heart failure (2013) - Pfizer : Lipids (2013) - Sanofi Aventis : Lipids (2013) - Siemens Healthcare : Markers (2013) 12/50

13 Agewall Stefan - Astra Zeneca : Platelet inhibition ( ) - Thermo Fischer Scientific : Cardiac markers ( ) Aladashvili Alexander Nothing to be declared ( ) Atalar Enver Nothing to be declared ( ) Averkov Oleg - GlaxoSmithKline : Antithrombotic (2013) - Medicines Company : Antithrombotic (2013) - Krka Pharma : Antithrombotic (2013) - Astra Zeneca : Antithrombotic ( ) - Boehringer-Ingelheim : Antithrombotic ( ) - Janssen-Cilag : Antithrombotic ( ) - Sanofi Aventis : Antithrombotic ( ) - Bayer Healthcare : Antithrombotic ( ) - Baxter : Esmolol ( ) - Novartis : Heart failure ( ) - Portola Pharmaceuticals : Antithrombotic (2014) - Bristol Myers Squibb : Antithrombotic (2014) - Apex : Antithrombotic (2014) - Sorbent : Heart failure (2014) - Amarin : Dyslipidemia ( ) - Astra Zeneca : Ahtithrombotic (2015) - Boehringer-Ingelheim : Ahtithrombotic (2015) - Janssen-Cilag : Ahtithrombotic (2015) 13/50

14 Averkov Oleg - Sanofi Aventis : Ahtithrombotic (2015) - Bayer Healthcare : Ahtithrombotic (2015) - Portola Pharmaceuticals : Ahtithrombotic (2015) - Bristol Myers Squibb : Ahtithrombotic (2015) - Apex : Ahtithrombotic (2015) - Sanofi Aventis : Dyslipidemia (2013) - Amarin : Dyslipidemia ( ) - Novartis : Heart failure ( ) - Portola Pharmaceuticals : Antithrombotic (2014) - Sorbent : Heart failure (2014) - Portola Pharmaceuticals : Ahtithrombotic (2015) Badimon Lina - Astra Zeneca : cardiovascular (2013) - Sanofi Aventis : cardiovascular (2013) - MSD-España : Lipids (2014) - Sanofi Aventis : lipids ( ) - Burson Masteller : nutrition ( ) - Astra Zeneca : thrombosis ( ) Baigent Colin - Astrazeneca : thrombosis ( ) - Bayer : Aspirin ( ) - Merck Sharp & Dohme : Cardiovascular disease ( ) 14/50

15 Baigent Colin - Abbott : Fish oil ( ) - Novartis : LCZ-696 ( ) - Novartis : Transplantation ( ) - Pfizer : Transplantation ( ) Bang Lia Evi E - Research funding (personal). - Novartis : LCZ696 (2013) - Amgen : Anti lipid drug (2013) - Merck Sharp & Dohme : Anti lipid drug (2013) - Astra Zeneca : Anti trombotic (2013) - Amgen : Lipid lowering drug (2014) - Astra Zeneca : Lipid lowering drug (2014) - Merck Sharp & Dohme : Lipid lowering drug (2014) - Amgen : Cardiovaskular (2015) - Astra Zeneca : Cardiovaskular (2015) - Bayer : Cardiovaskular (2015) - Sanofi Aventis : Cardiovaskular (2015) - Merck Sharp & Dohme : Cardiovaskular (2015) - GSK : Cardiovaskular (2015) - Sanofi Aventis : Anti lipid drug (2013) - GlaxoSmithKline : Anti lipid drug (2013) - Lilly : Anti lipid drug (2013) 15/50

16 Barrabes Jose A - Rovi : Antianginal agents (2013) - Bayer : Anticoagulant agents (2013) - Astra Zeneca : antiplatelet agents ( ) - Menarini : Antianginal agents ( ) - Astra Zeneca : Antiplatelet agents ( ) - GlaxoSmithKline : Participation in LATITUDE TIMI 60 study (losmapimod) (2015) Baumgartner Helmut - Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease ( ) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) ( ) - Abbott : transcather mitral valve repair (Mitraclip) ( ) - Edwards Lifesciences : transcatheter valve implantation ( ) - Direct Flow Medical : transcatheter valve implantation ( ) - Actelion : Bosentan for PAH treatment in congenital heart disease ( ) Becker David Nothing to be declared (2013) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) ( ) - Abbott : transcather mitral valve repair (Mitraclip) ( ) - Edwards Lifesciences : transcatheter valve implantation ( ) - Direct Flow Medical : transcatheter valve implantation ( ) - Krka Pharma : Cardiology ( ) - Bayer Healthcare : Cardiology (2015) Beishenkulov Medet Nothing to be declared ( ) 16/50

17 Bolognese Leonardo Budaj Andrzej - Eli Lilly, Daichhi Sankio, Abbott, Menarini, Astra : antiplatelet therapy, antianginal Rx, stents ( ) - Astra Zeneca : antiplatelet therapy ( ) - Sanofi Aventis : alirocumab ( ) - Bristol Myers Squibb/Pfizer : apixaban ( ) - Novartis : canakinumab ( ) - Boehringer-Ingelheim : dabigatran ( ) - GlaxoSmithKline : darapladib, losmapimod ( ) - Eisai : lorcaserin ( ) - Astra Zeneca : ticagrelor, dapagliflozin ( ) - Bristol Myers Squibb : apixaban ( ) - Novartis : canakinumab ( ) - Boehringer-Ingelheim : dabigatran ( ) - GlaxoSmithKline : darapladib, losmapimod ( ) - Eisai : lorcaserin ( ) - Astra Zeneca : ticagrelor, dapagliflozin ( ) Bueno Hector - BMS/Pfizer : Apixaban (2013) - Roche Pharma : Dalcetrapib (2013) - Novartis : Relaxin (2013) - Bayer Healthcare : Aspirin, rivaroxaban ( ) - Sanofi Aventis : Clopidogrel ( ) 17/50

18 Bueno Hector - Daiichi Sankyo : Prasugrel ( ) - Eli Lilly : Prasugrel ( ) - Astra Zeneca : Ticagrelor ( ) - Novartis : Serelaxin (2014) - Pfizer : Apixaban ( ) - Bristol Myers Squibb : Apixaban ( ) - Servier : ivabradine ( ) - Menarini : Ranolazine ( ) - Abbott : Absorb stent (2015) - Novartis : Serelaxin, ACZ696 (2015) - Ferrer Internacional : Trinomia (polypill) (2015) - Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015) E - Research funding (personal). - Astra Zeneca : Ticagrelor ( ) Bugiardini Raffaele Nothing to be declared ( ) Carerj Scipione Nothing to be declared ( ) Casselman Filip - Medtronic : Atrial fibrillation ( ) - Edwards Lifesciences : Minimally invasive cardiac surgery ( ) - Medtronic : Atrial fibrillation ( ) Chilingaryan Aram Nothing to be declared ( ) - Edwards Lifesciences : Minimally invasive cardiac surgery ( ) 18/50

19 Cuisset Thomas - Medicines Company : Anticoagulant agent (2013) - Eli Lilly : Antiplatelet (2013) - Astra Zeneca : Antiplatelet Drug (2013) - Daiichi Sankyo : Antiplatelet drug (2013) - Iroko Cardio : Antiplatelet drug (2013) - Biosensors : Device (2013) - Boston Scientific : Device (2013) - Terumo Inc : Device (2013) - Abbott Vascular : Device (2013) - Boston Scientific : DES ( ) - Biotronik : DES ( ) - Abbott Vascular : DES ( ) - Sanofi Aventis : Clopidogrel ( ) - Eli Lilly : Prasugrel ( ) - Eli Lilly : Medications (2013) - Biomatrix : DES ( ) - Europa : Education ( ) - Bayer : Rivaroxaban ( ) - Hexacath : Stent ( ) - Edwards Lifesciences : TAVI ( ) - Astra Zeneca : Ticagrelor ( ) 19/50

20 Eftychiou Christos Nothing to be declared ( ) Erol Cetin Etriby Adel Mohamad Kamal - Servier : Hypertension ( ) - Menarini : Hypertension ( ) Nothing to be declared ( ) Fitzsimons Donna Nothing to be declared ( ) - Amgen : FH Tratment options (2014) Gaemperli Oliver Nothing to be declared (2013) - Biosensors : Stents (2014) - Biosensors : Axxess Bifurcation Stent (2015) - Abbott Vascular : MitraClip (2015) Ginghina Carmen Nothing to be declared ( ) - Biosensors : Travel Grant to AsiaPCR 2015 (2015) - - LABORMED ALVOGEN ( Tabloul clinic al arteriopatiei periferice ) - ALFA WASSERMMAN ( Medicatia in arteriopatiile periferice Vessel Due ) : - LABORMED ALVOGEN ( Tabloul clinic al arteriopatiei periferice ) - ALFA WASSERMMAN ( Medicatia in arteriopatiile periferice Vessel Due ) (2014) Grosu Aurel Nothing to be declared ( ) Gudnason Thorarinn Nothing to be declared (2015) - Pfizer : NOAC (2014) E - Research funding (personal). - Novartis : Heart failure (2013) 20/50

21 Halle Martin - Merck Sharp & Dohme : diabetes, prevention (2013) - Novartis : transplantation (2013) - Roche Pharma : diabetes, dyslipidemia ( ) - Berlin Chemie AG : diabetes, prevention ( ) - Sanofi Aventis : diabetes ( ) - Novartis : heart failure ( ) - Merck Sharp & Dohme : lipids ( ) - Pfizer : coagulation (2015) - Daiichi Sankyo : coagulation, diabetes (2015) - Berlin Chemie AG : diabetes (2015) - Roche Pharma : diabetes (2015) - Techniker Krankenkasse : health insurance company (2015) - Abbott : lipids (2015) Hamm Christian - Techniker Krankenkasse Hamburg : Health Insurance Company. Monitoring of Pilot Study ( ) - Iroko Cardio : drugs (2013) - Roche Diagnostics : marker (2013) - Medtronic : PCI (2013) - Astra Zeneca : drugs ( ) - Boehringer-Ingelheim : drugs ( ) - Daiichi Sankyo : drugs ( ) - Novartis : drugs ( ) 21/50

22 Hamm Christian - Pfizer : drugs ( ) - Sanofi Aventis : drugs ( ) - GlaxoSmithKline : drugs ( ) - Lilly : drugs ( ) - Berlin Chemie AG : drugs ( ) - Heart.org : drugs ( ) - Bayer Healthcare : drugs ( ) - Gilead : drugs ( ) - Medicines Company : drugs ( ) - Merck Sharp & Dohme : drugs ( ) - Abbott Vascular : interventional devices ( ) - BRAHMS GmbH : markers ( ) - Siemens Healthcare : MRI ( ) - Boston Scientific : PCI ( ) - TIMI group : study advisor ( ) - Roche Diagnostics : biomarker ( ) - Correvio : drugs ( ) - Medtronic : PCI, Valves ( ) - Edwards Lifesciences : Valves ( ) - Symetis SA : Valves ( ) - Deutsche Forschungsgemeinschaft : experimental ( ) - German Research Foundation : experimental studies ( ) 22/50

23 Held Claes - Astrazeneca : cardiology ( ) - Roche Diagnostics : cardiology ( ) - Astra Zeneca : cardiology ( ) - Pfizer : cardiology ( ) - GlaxoSmithKline : cardiology ( ) - Bristol Myers Squibb : cardiology ( ) Hildick-Smith David - Abbott Laboratories : Advisory Board ( ) - AGA : Advisory Board and proctoring ( ) - Medtronic : proctor ( ) Huber Kurt - W.L. Gore & associates : Advisory Board, Research ( ) C - Receipt of royalties for intellectual property. - Terumo Inc : Advisory Board ( ) - Abbott Laboratories : stents ( ) - Pfizer : atorvastatin, edoxaban ( ) - Medicines Company : bivalirudin; cangrelor ( ) - BRAHMS GmbH : copeptin assay ( ) - Boehringer-Ingelheim : dabigatran ( ) - Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : prasugrel; abciximab ( ) - Bayer : rivaroxaban ( ) - Astra Zeneca : ticagrelor; rosuvastatin ( ) 23/50

24 Huber Kurt - Bristol Myers Squibb / Pfizer : Apixaban ( ) - Daiichi Sankyo : edoxaban ( ) - Amgen : PCSK9-inhibition ( ) Iliodromitis Efstathios Nothing to be declared ( ) James Stefan - Sanofi Aventis : coagulation inhibition ( ) - Merck Sharp & Dohme : coagulation inhibition ( ) - Medtronic : Stents and valves ( ) - Astra Zeneca : Platelet inhibition ( ) - Eli Lilly : platelet inhibition ( ) - Medtronic : thrombus asp catheter ( ) - Terumo Inc : thrombus asp catheter ( ) - Vascular solutions : thrombus asp catheter ( ) - Astra Zeneca : platelet inhibition ( ) Kedev Sasko - Astra Zeneca : Anti thrombotics (2015) - Medtronic : Honaria (2013) - Abbott Vascular : Speaker fees (2013) - Boston Scientific : Speaker fees ( ) - Meril : Speaker fees (2014) - Medtronic : Speaker fees ( ) - Terumo Inc : Speaker fees (2015) 24/50

25 Koning Rene Nothing to be declared ( ) - Lilly : cardiology (2015) - Abbott Vascular : cardiology (2015) - Committee Member of CFCI (congres francophone Paris) : CARDIOLOGY (2015) - Biosensors : CARDIOLOGY (2015) - Boston Scientific : CARDIOLOGY (2015) - Biotronik : CARDIOLOGY (2015) - Braun : CARDIOLOGY (2015) Larsen Alf Inge Nothing to be declared ( ) Latkovskis Gustavs - Sanofi Aventis : Antiplatelets (2013) - Takeda Pharmaceuticals : Cardiovascular risk (2013) - Novo-Nordisk : Diabetes (2013) - Servier : Hypertension (2013) - Abbott Laboratories : lipid-lowering drugs (2013) - GlaxoSmithKline : LPH (2013) - Pfizer : Dyslipidemias, anticoagulants ( ) - Bayer : Anticoagulants ( ) - Boehringer-Ingelheim : Anticoagulants ( ) - Berlin Chemie AG : Antihypertensive agents ( ) - Merck Serono : Beta blockers ( ) 25/50

26 Latkovskis Gustavs - University of Latvia : Education ( ) - Latvian Research Institute of Cardiology : genetics of CVD, pharmacogenetics ( ) - Siemens Healthcare : hs-troponin I ( ) - Astra Zeneca : lipid-lowering drugs, anti platelets ( ) - Servier : Hypertension, heart rate ( ) - Latvian Association of Human Genetics : Lecture on familial hypercholesterolemia (2015) - Mylan : Lipid lowering therapies (2015) - Latvian Council of Science : Genetics of CVD (2013) - Latvian Council of Science : Trimethylamine N-oxide and glucose metabolism; familial hypercholesterolemia. (2015) E - Research funding (personal). - Bayer : Anticoagulation (2013) - Merck Serono : bisoprolol and amlodipine combination ( ) - Pharma and Chemistry Competence Centre of Latvia : Statin myopathy ( ) Lewis Basil S - Sanofi Aventis : Anti-diabetics (2013) - Astra Zeneca : Antithrombotics ( ) - Merck Sharp & Dohme : Anti-thrombotics ( ) - Amgen : Lipidology ( ) - Pfizer : Antithrombotics ( ) - GlaxoSmithKline : Anti-atherosclerosis (2013) - Daiichi Sankyo : Diabetes, antithrombotics (2013) - Eli Lilly : Heart failure (2013) 26/50

27 Lewis Basil S - Sanofi Aventis : Lipidology (2013) - Novartis : Heart failure ( ) - Amgen : Lipidology ( ) - Pfizer : Lipidology ( ) - Astra Zeneca : Diabetes ( ) - Pfizer : Diabetes ( ) Lip Gregory Y H - Astellas : atrial fibrillation, thrombosis (2013) - Biotronik : atrial fibrillation ( ) - Boehringer-Ingelheim : atrial fibrillation, thrombosis ( ) - Daiichi Sankyo : atrial fibrillation, thrombosis ( ) - Pfizer : atrial fibrillation, thrombosis ( ) - Bayer Healthcare : atrial fibrillation, thrombosis ( ) - Bristol Myers Squibb : atrial fibrillation, thrombosis ( ) - Medtronic : atrial fibrillation ( ) - Roche Diagnostics : anticoagulation (2015) - Bayer : atrial fibrillation, thrombosis (2013) - Daiichi Sankyo : atrial fibrillation, thrombosis ( ) Magri Caroline Jane Nothing to be declared ( ) Marandi Toomas - Portola Pharmaceuticals : Betrixaban, investigator ( ) - Boehringer-Ingelheim : Empagliflozin, investigator ( ) - Astra Zeneca : Myocardial infarction, speaker ( ) 27/50

28 Matetzky Shlomi Nothing to be declared ( ) Milicic Davor - Astra Zeneca : cardiovascular drugs ( ) - Boehringer-Ingelheim : cardiovascular drugs ( ) - Pfizer : cardiovascular drugs ( ) - Sanofi Aventis : cardiovascular drugs ( ) - Bayer Healthcare : cardiovascular drugs ( ) - Krka Pharma : cardiovascular drugs ( ) - Pliva, : cardiovascular drugs ( ) - Thoratec : mechanical circulatory support ( ) - Marck Medical : mechanical circulatory support ( ) Mimoso Jorge M Vieira - University of Zagreb : Antithrombotic drugs (2015) E - Research funding (personal). - University of Zagreb : Platelet reactivity to antithrombotic drugs ( ) - Servier : Ivabradine (2013) - JaBA Recordati : Pitavastatine (2014) - Bayer : Xarelto (2014) - Boehringer-Ingelheim : Dabigatrano (2015) - Astra Zeneca : Ticagrelor (2015) - Astra Zeneca : Ticagrelor (2013) Mourali Mohamed Sami Nothing to be declared ( ) Mussagaliyeva Aisulu - Servier : Stable angina ( ) 28/50

29 Mussagaliyeva Aisulu - Servier : Stable angina ( ) Najafov Ruslan Nothing to be declared ( ) Nedeljkovic Milan Nothing to be declared ( ) Neumann Franz Josef - Astra Zeneca : Antiplatelet therapy ( ) - Daiichi Sankyo : Antiplatelet therapy ( ) - Lilly : Antiplatelet therapy ( ) - Boehringer-Ingelheim : Antithrombotic Therapy ( ) - Medicines Company : Antithrombotic therapy ( ) - Edwards Lifesciences : Catheter Valves ( ) - Boston Scientific : Interventional Cardiology ( ) - Medtronic : Interventional Cardiology ( ) - Biotronik : Interventional Cardiology ( ) - Biotronik : Interventional Cardiology ( ) - Braun : Interventional Cardiology ( ) - Edwards Lifesciences : Transcatheter Valves ( ) Parkhomenko Alexander - Servier : trimetazidin, rivaroxaban, ticagrelor ( ) - BHFZ : corvitin (2015) - Bayer Healthcare : rivaroxaban (2015) - Astra Zeneca : ticagrelor (2015) - Servier : trimetazidine (2015) 29/50

30 Parkhomenko Alexander - Bayer : rivaroxabane ( ) C - Receipt of royalties for intellectual property. - BHFZ : corvitine ( ) - European Research Foundation FP7 : biomarkers (2015) Pereira Bruno Nothing to be declared (2013) - Astra Zeneca : Speaker Fees (2014) Peters Ron J G Nothing to be declared (2013) - Abbott Vascular : Speaker Fees (2014) - Merck Sharp & Dohme : Speaker Fees (2015) - Boehringer-Ingelheim : anticoagulants (2014) - Daiichi Sankyo : antiplatelet agents (2014) - Amgen : lipid lowering (2014) - Sanofi Aventis : lipid lowering (2014) - Merck Sharp & Dohme : lipid lowering (2014) - Astrazeneca : lipid lowering (2014) - Sanofi Aventis : alirocumab (2015) - Amgen : evolocumab (2015) - Astrazeneca : ticagrelor (2015) - Philips Healthcare : DirectLife activity program (2015) Piepoli Massimo Francesco Nothing to be declared ( ) - weight watchers international : weight reduction and physical fitness (2015) 30/50

31 Pietila Mikko Juhani - St Jude Medical : Invasive cardiology (2013) - Pfizer : Secondary prevention (2013) - Astra Zeneca : Acute coronary syndromes ( ) - Bayer : Prevention of thromboembolism ( ) - Servier : Heart failure (2014) - Novartis : Heart failure (2015) Postadzhiyan Arman - Astra Zeneca : ACS ( ) - Boehringer-Ingelheim : AF ( ) - Bayer : AF ( ) - Pfizer : AF (2015) - Servier : arterial hypertension (2015) - Merck Sharp & Dohme : arterial hypertension (2015) - Berlin Menarini : arterial hypertension (2015) - Sanofi Aventis : lipids (2015) Richter Dimitrios - Menarini : CAD (2013) - Novartis : hypertension ( ) - Abbott : Lipids ( ) - Amgen : lipids ( ) - Unilever : lipids ( ) - Merck Sharp & Dohme : lipids ( ) - Vianex : lipids ( ) 31/50

32 Richter Dimitrios - Swisspharma : lipids-hypertension ( ) - Astra Zeneca : lipids-thrombosis ( ) - Pfizer : lipids-thrombosis ( ) - Boehringer-Ingelheim : thrombosis ( ) - Bayer Healthcare : Thrombosis ( ) - Menarini : CAD- hypertension ( ) - Sanofi Aventis : Lipids ( ) - Lilly : Lipids ( ) - Angelini : Lipids ( ) - Galenica : Lipids ( ) - Winmedica : lipids-thrombosis ( ) - Actavis : Lipids, thrombosis (2015) Rickli Hans - Boehringer-Ingelheim : Dabigatran (2013) - Daiichi Sankyo : Prasugrel ( ) - Servier : Ivabradin ( ) - Bayer Healthcare : Rivaroxaban ( ) - Astra Zeneca : Ticagrelor ( ) Rosemann Thomas - Menarini : general internal medicine ( ) - Novartis : Lecture about personalized medicine (2014) - Menarini : Hypertension (2015) - Menarini : Hypertension (2015) 32/50

33 Sechtem Udo - Pfizer : Drugs ( ) - Berlin Chemie AG : Drugs (2013) - Astra Zeneca : Drugs ( ) - Pfizer : Drugs ( ) - Siemens Healthcare : Drugs ( ) - Bayer Vital : Drugs ( ) - Boehringer-Ingelheim : Drugs ( ) - Bayer Healthcare : Drugs ( ) - Berlin Chemie AG : cath lab equipment (2014) - Bristol Myers Squibb : Drugs (2015) Serpytis Pranas Sinnaeve Peter R - European Research Foundation FP7 : CULPRIT-SHOCK study, National Investigator ( ) - Astra Zeneca : ACS (2013) - GlaxoSmithKline : ACS & CAD (2013) - Abbott Vascular : PCI (2013) - Lilly : ACS ( ) - Bayer : ACS & AF ( ) - Boehringer-Ingelheim : ACS & AF ( ) - Merck Sharp & Dohme : CAD & ACS ( ) - Duke University : trials ( ) - Sanofi Aventis : trials, consultancy ( ) 33/50

34 Sinnaeve Peter R - GlaxoSmithKline : ACS & CAD, trials ( ) - Astra Zeneca : ACS, trials ( ) - Novartis : trials ( ) - Astra Zeneca : basic science and epidemiology ( ) - Flemish Government : basic science ( ) Steg Philippe Gabriel - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : Contrast agents (2013) - Vivus : Drugs for obesity ( ) - Servier : antianginal agents ( ) - Bayer : anticoagulants ( ) - Astra Zeneca : antiplatelet agents ( ) - Daiichi Sankyo : antiplatelet agents ( ) - Boehringer-Ingelheim : antithrombotics ( ) - Sanofi Aventis : antithrombotics ( ) - GlaxoSmithKline : antithrombotics ( ) - Medicines Company : antithrombotics ( ) - Bristol Myers Squibb : antithrombotics ( ) - Lilly : antithrombotics and lipid lowering drugs ( ) - Amarin : Lipid compounds ( ) - Medtronic : stents ( ) - Regado Biosciences : Steering Committee for trial of anticoagulant (2014) - Janssen-Cilag : antithrombotics (2015) 34/50

35 Steg Philippe Gabriel - Novartis : consulting (2015) - Pfizer : Events adjudication committee (2015) - CSL Behring : lipid lowering drugs (2015) C - Receipt of royalties for intellectual property. - Aterovax : Biomarkers ( ) - Sanofi Aventis : Clinical trial on lipids ( ) - Servier : Registry on coronary artery disease ( ) Studencan Martin - GlaxoSmithKline : Dabigatran (2013) - MSD : Esetimibe, Inegy ( ) Swanson Neil Nothing to be declared (2013) - Astra Zeneca : Antiplatelet drugs (ATLANTIC trial) ( ) Terzic Ibrahim Nothing to be declared ( ) - Astra Zeneca : Antiplatelet drugs (THEMIS trial) ( ) - Servier : Preduktal - Investigator in ATPCI study (2015) - Sadra Medical : Odyssey study (2015) Tsioufis Costas Nothing to be declared (2013) - Astra Zeneca : Honoraria, Travel Expenses ( ) - Bayer : Honoraria, Travel Expenses ( ) - Boehringer-Ingelheim : Honoraria, Travel Expenses ( ) - Medtronic : Honoraria, Travel Expenses ( ) 35/50

36 Tsioufis Costas - Novartis : Honoraria, Travel Expenses ( ) - Pfizer : Honoraria, Travel Expenses ( ) - St Jude Medical : Honoraria, Travel Expenses ( ) - Sanofi Aventis : Honoraria, Travel Expenses ( ) - Menarini : Honoraria, Travel Expenses ( ) - Recordati International : Funding ( ) - St Jude Medical : Renal denervation ( ) Vrints Christian Joseph Marie Weidinger Franz Nothing to be declared (2015) - Medtronic : pacing, ICD & stents ( ) - Bayer Healthcare : Rivaroxaban (2013) - Astra Zeneca : Ticagrelor, Saxagliptin (2013) - Pfizer : Apixaban ( ) - Daiichi Sankyo : Edoxaban ( ) - Lilly : Prasugrel ( ) - Biotronik : Stents ( ) - Novartis : Heart failure ( ) - Astra Zeneca : Ticagrelor ( ) - Daiichi Sankyo : Antiplatelet therapy (2013) - Merck Sharp & Dohme : Lipid lowering ( ) - Biotronik : Drug-eluting stent (2014) 36/50

37 Weidinger Franz - Sanofi Aventis : Lipid lowering ( ) Widimsky Petr - Terumo Inc : Drug-eluting stent (2015) - Sanofi Aventis : Antithrombotic agents ( ) - Servier : Antiischemic agents ( ) - Astra Zeneca : Antithrombotic agents ( ) - Bayer : Antithrombotic agents ( ) - Boehringer-Ingelheim : Antithrombotic agents ( ) - Daiichi Sankyo : Antithrombotic agents ( ) - Eli Lilly : Antithrombotic agents ( ) - Abbott : Stents ( ) - Medtronic : Stents ( ) Zamorano Gomez Jose Luis - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013) - Philips : 3D echo (2014) - Toshiba medical imaging : fusion imaging 3D echo CT (2014) - Astra Zeneca : Speaker fee for 1 talk in 2014 (2014) - MSD : CV risk factors ( ) - Abbott : Lecturing (2015) - Astra Zeneca : Lecturing (2015) - Pfizer : Lecturing (2015) - Sorin Group : Respicardia echo protocol (2015) 37/50

38 Zamorano Gomez Jose Luis - European Research FP7 : CV Imaging (2013) - Servier : Imaging in ISchemic patients (2013) - Siemens Healthcare : 3d echo software and free style echo ( ) - Toshiba medical imaging : Fusion Imaging (2015) C - Receipt of royalties for intellectual property. - Springer : ESC Textbook of CV Imaging (2013) - Amgen : Clinical trial ( ) - Novartis : Clinical trial ( ) - Ikaria : Clinical trial ( ) 38/50

39 Committee for Practice Guidelines MEMBERS Aboyans Victor Nothing to be declared (2013) - Astra Zeneca : Antithrombotics (2014) - Sanofi Aventis : Hyperlipidemia (2014) - Boehringer-Ingelheim : Oral anticoagulation (2014) - Pfizer/BMS alliance : Oral anticoagulation (2014) - Novartis : Hypertension ( ) - Bayer Healthcare : Oral anticoagulation ( ) - Merck Sharp & Dohme : Antithrombotics (2015) Achenbach Stephan - Bayer : Anticoagulation (2013) - Behring : Anticoagulation (2013) - Astra Zeneca : Antiplatelet Therapy (2013) - Abbott : Coronary Intervention (2013) - Siemens Healthcare : CT (2013) - Servier : Imaging (2013) - Guerbet : Imaging (2013) - Abbott : Coronary Intervention ( ) - Siemens Healthcare : Imaging ( ) Agewall Stefan - Böhringer Ingelheim : Anticoagulatn treatment (2013) - Roche Diagnostics : Cardiac markers (2013) - Orion : Heart failure (2013) 39/50

40 Committee for Practice Guidelines MEMBERS Agewall Stefan - Pfizer : Lipids (2013) - Sanofi Aventis : Lipids (2013) - Siemens Healthcare : Markers (2013) - Astra Zeneca : Platelet inhibition ( ) - Thermo Fischer Scientific : Cardiac markers ( ) Badimon Lina - Astra Zeneca : cardiovascular (2013) - Sanofi Aventis : cardiovascular (2013) - MSD-España : Lipids (2014) - Sanofi Aventis : lipids ( ) - Burson Masteller : nutrition ( ) - Astra Zeneca : thrombosis ( ) Baron Esquivias Gonzalo - Astrazeneca : thrombosis ( ) - Bayer : Anticoagulation ( ) - Boehringer-Ingelheim : Anticoagulation ( ) - Daiichi Sankyo : Anticoagulation ( ) - Pfizer : Anticoagulation ( ) - Menarini : Ischemic disease (2015) - Laboratorios Rovi : Ivabradine (2015) - Biotronik : Vasovagal syncope & Pacing (2013) - Bayer : Anticoagulation (2015) 40/50

41 Committee for Practice Guidelines MEMBERS Baumgartner Helmut - Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease ( ) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) ( ) - Abbott : transcather mitral valve repair (Mitraclip) ( ) - Edwards Lifesciences : transcatheter valve implantation ( ) - Direct Flow Medical : transcatheter valve implantation ( ) - Actelion : Bosentan for PAH treatment in congenital heart disease ( ) Bax Jeroen Nothing to be declared ( ) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) ( ) - Abbott : transcather mitral valve repair (Mitraclip) ( ) - Edwards Lifesciences : transcatheter valve implantation ( ) - Direct Flow Medical : transcatheter valve implantation ( ) - Servier : Farma (2013) - Edwards Lifesciences : Heart Valves (2013) - GE Healthcare : Imaging (2013) - Lantheus Inc : Imaging (2013) - Boston Scientific : Pacing (2013) - Medtronic : Pacing (2013) - St Jude Medical : Pacing (2013) - Biotronik : Pacing (2013) Bueno Hector - BMS/Pfizer : Apixaban (2013) 41/50

42 Committee for Practice Guidelines MEMBERS Bueno Hector - Roche Pharma : Dalcetrapib (2013) - Novartis : Relaxin (2013) - Bayer Healthcare : Aspirin, rivaroxaban ( ) - Sanofi Aventis : Clopidogrel ( ) - Daiichi Sankyo : Prasugrel ( ) - Eli Lilly : Prasugrel ( ) - Astra Zeneca : Ticagrelor ( ) - Novartis : Serelaxin (2014) - Pfizer : Apixaban ( ) - Bristol Myers Squibb : Apixaban ( ) - Servier : ivabradine ( ) - Menarini : Ranolazine ( ) - Abbott : Absorb stent (2015) - Novartis : Serelaxin, ACZ696 (2015) - Ferrer Internacional : Trinomia (polypill) (2015) - Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015) E - Research funding (personal). - Astra Zeneca : Ticagrelor ( ) Carerj Scipione Nothing to be declared ( ) Erol Cetin - Servier : Hypertension ( ) - Menarini : Hypertension ( ) 42/50

43 Committee for Practice Guidelines MEMBERS Fitzsimons Donna Nothing to be declared ( ) - Amgen : FH Tratment options (2014) Gaemperli Oliver Nothing to be declared (2013) - Biosensors : Stents (2014) - Biosensors : Axxess Bifurcation Stent (2015) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015) Kirchhof Paulus - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013) - Boehringer-Ingelheim : cardiovascular ( ) - Daiichi Sankyo : cardiovascular ( ) - Medtronic : cardiovascular ( ) - Pfizer : cardiovascular ( ) - St Jude Medical : cardiovascular ( ) - Sanofi Aventis : cardiovascular ( ) - Meda pharma : cardiovascular ( ) - Bristol Myers Squibb : cardiovascular ( ) - Merck Sharp & Dohme : cardiovascular ( ) - Medscape : cardiovascular ( ) - Bayer Healthcare : cardiovascular (2015) - Correvio : cardiovascular (2015) - Remedica : cardiovascular (2015) 43/50

44 Committee for Practice Guidelines MEMBERS Kirchhof Paulus - Boehringer-Ingelheim : cardiovascular (2013) - Bayer Healthcare : cardiovascular (2013) - Gilead : cardiovascular (2013) - BMS / Pfizer alliance : cardiovascular (2013) - St Jude Medical : cardiovascular ( ) - Sanofi Aventis : cardiovascular ( ) - Meda pharma : cardiovascular ( ) - Daiichi Sankyo : cardiovascular ( ) - British Heart Foundation : cardiovascular ( ) - BMS / Pfizer alliance : cardiovascular ( ) - Leducq Foundation : cardiovascular ( ) - European Union FP7 : cardiovascular ( ) - European Union horizon2020 : cardiovascular ( ) Kolh Philippe H 2015) - German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular ( B.Braun : Surgical instruments ( ) - Astra Zeneca : Antiplatelet agents ( ) - St Jude Medical : Cardiac valves (2013) - Boston Scientific : Coronary stents (2013) - Siemens Healthcare : Medical imaging (2013) - Johnson & Johnson : Thoracoscopic devices (2013) 44/50

45 Committee for Practice Guidelines MEMBERS Kolh Philippe H - Edwards Lifesciences : Cardiac valves ( ) - Medtronic : Cardiac valves ( ) Lancellotti Patrizio - Servier : Heart Failure (2013) - Abbott : MitraClip (2013) - Menarini : nebivolol (2014) - St Jude Medical : Heart Failure (2015) - Astrazeneca : Dyslipidemia (2013) - Boston Scientific : CRT (2014) - Servier : procoralan (2014) - Daiichi Sankyo : Teaching course on imaging (2015) Lip Gregory Y H - Actelion : Pulmonary Hypertension (2013) - Astellas : atrial fibrillation, thrombosis (2013) - Biotronik : atrial fibrillation ( ) - Boehringer-Ingelheim : atrial fibrillation, thrombosis ( ) - Daiichi Sankyo : atrial fibrillation, thrombosis ( ) - Pfizer : atrial fibrillation, thrombosis ( ) - Bayer Healthcare : atrial fibrillation, thrombosis ( ) - Bristol Myers Squibb : atrial fibrillation, thrombosis ( ) - Medtronic : atrial fibrillation ( ) - Roche Diagnostics : anticoagulation (2015) 45/50

46 Committee for Practice Guidelines MEMBERS Lip Gregory Y H - Bayer : atrial fibrillation, thrombosis (2013) - Daiichi Sankyo : atrial fibrillation, thrombosis ( ) Nihoyannopoulos Petros Nothing to be declared ( ) - GSK : Consultant for Imaging studies (2013) Piepoli Massimo Francesco Nothing to be declared ( ) Ponikowski Piotr - Bayer : anticoagulant (2013) - Bristol Myers Squibb : anticoagulant (2013) - ROSCHE : diabetes (2013) - Boehringer-Ingelheim : anticoagulant ( ) - Respicardia : anticoagulant ( ) - Johnson & Johnson : heart failure ( ) - Pfizer : heart failure, anticoagulant ( ) - Abbott Vascular : devices ( ) - Novartis : heart failure ( ) - Cardiorentis : heart failure ( ) - Bayer Healthcare : heart failure ( ) - Vifor Pharma ltd : heart failure ( ) - CIBIEM : heart failure ( ) - Servier : heart failure, coronary artery disease ( ) - Amgen : heart failure, lipids ( ) - MSD : lipids (2014) 46/50

47 Committee for Practice Guidelines MEMBERS Ponikowski Piotr - Astra Zeneca : acute coronary syndrome ( ) - Boehringer-Ingelheim : anticoagulant, diabetes (2015) - Respicardia : devices (2015) - BioControl : devices (2015) - DC Device : devices (2015) - Celladon : heart failure (2015) - Vifor Pharma ltd : heart failure (2014) - MSD : lipids (2014) - Astra Zeneca : acute coronary syndrome ( ) - Respicardia : anticoagulant ( ) - Novartis : heart failure ( ) - Cardiorentis : heart failure ( ) - Bayer Healthcare : heart failure ( ) - CIBIEM : heart failure ( ) - Servier : heart failure, coronary artery disease ( ) - Amgen : heart failure, lipids ( ) - BioControl : devices (2015) - DC Device : devices (2015) - Celladon : heart failure (2015) - Vifor Pharma ltd : heart failure (2013) - Singulex : biomarkers (2015) 47/50

48 Committee for Practice Guidelines MEMBERS Roffi Marco - Daiichi Sankyo : antiplatelet therapy (2013) - Lilly : antiplatelet therapy (2013) - Astra Zeneca : antipletelet therapy (2013) - Johnson & Johnson : coronary catheters (2014) - Biosensors : devices ( ) - Boston Scientific : devices ( ) - Medtronic : devices ( ) - Biotronik : devices ( ) - Abbott Vascular : devices ( ) Torbicki Adam - Bristol Myers Squibb : Pulmonary arterial hypertension ( ) - GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan ( ) - Lilly : pulmonary arterial hypertension - ambrisentan ( ) - Actelion : pulmonary arterial hypertension - macitentan, selexipag ( ) - Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto ( ) - AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015) - Bayer Healthcare : Pulmonary hypertension ( ) Vaz Carneiro Antonio Nothing to be declared (2015) Windecker Stephan - AbbVie : Oncology ( ) - Astra Zeneca : Antiplatelet drug (2013) - Eli Lilly : Antiplatelet drug (2013) 48/50

49 Committee for Practice Guidelines MEMBERS Windecker Stephan - Abbott : Stent (2013) - Medtronic : Stent (2013) - Biotronik : Stent (2013) - Astra Zeneca : Antiplatelet therapy ( ) - Eli Lilly : Antiplatelet therapy ( ) - Bayer Healthcare : Antithrombotic drug ( ) - Abbott : Stent and Heartvalvetherapy ( ) - Biosensors : Stents ( ) - Boston Scientific : Stents ( ) - Medtronic : TAVI, Stent (2015) - Edwards Lifesciences : Transcatheter heart valves (2015) - St Jude Medical : OCT ( ) - Biotronik : Stent ( ) - Medtronic : Stent and Heartvalves (2014) - Medicines Company : Antithrombotic therapy ( ) - Johnson & Johnson : Catheters ( ) - Edwards Lifesciences : Heartvalves ( ) - Abbott : Stent ( ) - Boston Scientific : Stent and Heartvalves ( ) Zamorano Gomez Jose Luis - Daiichii : Atrial Fib (2013) - Merck Sharp & Dohme : Lipid Lowering (2013) 49/50

50 Committee for Practice Guidelines MEMBERS Zamorano Gomez Jose Luis - Philips : 3D echo (2014) - Toshiba medical imaging : fusion imaging 3D echo CT (2014) - Astra Zeneca : Speaker fee for 1 talk in 2014 (2014) - MSD : CV risk factors ( ) - Abbott : Lecturing (2015) - Astra Zeneca : Lecturing (2015) - Pfizer : Lecturing (2015) - Sorin Group : Respicardia echo protocol (2015) - European Research FP7 : CV Imaging (2013) - Servier : Imaging in ISchemic patients (2013) - Siemens Healthcare : 3d echo software and free style echo ( ) - Toshiba medical imaging : Fusion Imaging (2015) C - Receipt of royalties for intellectual property. - Springer : ESC Textbook of CV Imaging (2013) - Amgen : Clinical trial ( ) - Novartis : Clinical trial ( ) - Ikaria : Clinical trial ( ) 50/50